Robert E. Landry - Feb 2, 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Feb 2, 2024
Transactions value $
-$117,227
Form type
4
Date filed
2/6/2024, 04:08 PM
Previous filing
Feb 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $152K +400 +1.7% $378.98 24K Feb 2, 2024 Direct
transaction REGN Common Stock Tax liability -$269K -281 -1.17% $956.65 23.7K Feb 2, 2024 Direct
holding REGN Common Stock 270 Feb 2, 2024 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -400 -3.28% $0.00 11.8K Feb 2, 2024 Common Stock 400 $378.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.